Show simple item record

dc.contributor.authorBhaludin, BN
dc.contributor.authorTunariu, N
dc.contributor.authorSenthivel, N
dc.contributor.authorBabiker, A
dc.contributor.authorSoneji, ND
dc.contributor.authorHujairi, N
dc.contributor.authorSharma, B
dc.contributor.authorMcGrath, SE
dc.contributor.authorOkines, AF
dc.contributor.authorRing, AE
dc.contributor.authorMessiou, C
dc.contributor.authorDowney, K
dc.contributor.authorKoh, D-M
dc.coverage.spatialEngland
dc.date.accessioned2022-08-23T10:07:14Z
dc.date.available2022-08-23T10:07:14Z
dc.date.issued2022-06-07
dc.identifierARTN 26
dc.identifier10.1186/s40644-022-00464-4
dc.identifier.citationCancer Imaging, 2022, 22 (1), pp. 26 -
dc.identifier.issn1740-5025
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5306
dc.identifier.eissn1470-7330
dc.identifier.eissn1470-7330
dc.identifier.doi10.1186/s40644-022-00464-4
dc.description.abstractBACKGROUND: The assessment of metastatic breast cancer (MBC) can be limited with routine imaging such as computed tomography (CT) especially in bone-only or bone-predominant disease. This analysis investigates the effects of the use of WBMRI in addition to the use of routine CT, bone scintigraphy (BS) and fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography (FDG-PET/CT) on influencing systemic anti-cancer treatment (SACT) decisions in patients with known MBC. METHODS: MBC patients undergoing SACT who had WBMRI undertaken within 8 weeks of either a routine CT, BS or FDG-PET/CT were reviewed retrospectively. The clinical indications for undertaking the WBMRI examinations were recorded. Data on the extent and distribution of the disease were collected and discordance/concordance of disease status across the imaging modalities were compared. SACT decisions at each time point were also evaluated. RESULTS: There were 105 MBC patients with 148 WBMRI studies paired with CT, BS or FDG-PET/CT. 50 pairs (33.8%) showed differences in the extent of disease, with 44 pairs due to additional sites (AS) reported on WBMRI alone. 81 patients (Group 1) had one WBMRI paired with routine imaging due to a variety of indications, with clinical symptoms (such as bone pain) being the most common (24.7%). 24 patients (Group 2) had more than one WBMRI study paired with routine imaging comprising 67 pairs. 13/67 pairs (19.4%) showed discordance in assessments. 10/13 pairs had progressive disease (PD) reported on WBMRI alone. SACT change due to AS reported on WBMRI alone occurred in 21/23 pairs (91.3%) in Group 1. SACT change due to PD reported on WBMRI alone in Group 2 occurred in 6/14 pairs (42.9%). SACT change due to AS/PD in both groups occurred in 11/102 pairs (10.8%) with known invasive ductal carcinoma (IDC) and 13/28 pairs (46.4%) with invasive lobular carcinoma (ILC). CONCLUSIONS: The use of WBMRI in MBC led to earlier recognition of PD and SACT change compared with the other imaging modalities. A higher proportion of discordant response assessments and SACT changes were observed in ILC compared with IDC in our patient group, although larger-scale studies are required to investigate this further.
dc.formatElectronic
dc.format.extent26 -
dc.languageeng
dc.language.isoeng
dc.publisherBMC
dc.relation.ispartofCancer Imaging
dc.rights.urihttps://creativecommons.org/publicdomain/zero/1.0/
dc.subjectCancer treatment
dc.subjectDiffusion-weighted imaging
dc.subjectMetastatic breast cancer
dc.subjectResponse assessment
dc.subjectWhole-body magnetic resonance imaging
dc.subjectBreast Neoplasms
dc.subjectFemale
dc.subjectFluorodeoxyglucose F18
dc.subjectHumans
dc.subjectMagnetic Resonance Imaging
dc.subjectPositron Emission Tomography Computed Tomography
dc.subjectPositron-Emission Tomography
dc.subjectRetrospective Studies
dc.subjectWhole Body Imaging
dc.titleDoes the addition of whole-body MRI to routine imaging influence real-world treatment decisions in metastatic breast cancer?
dc.typeJournal Article
dcterms.dateAccepted2022-05-26
dc.date.updated2022-08-23T10:06:43Z
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1186/s40644-022-00464-4
rioxxterms.licenseref.startdate2022-06-07
rioxxterms.typeJournal Article/Review
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/35672838
pubs.issue1
pubs.organisational-group/ICR
pubs.publication-statusPublished online
pubs.volume22
dc.contributor.icrauthorSharma, Bhupinder
icr.provenanceDeposited by Mr Arek Surman on 2022-08-23. Deposit type is initial. No. of files: 1. Files: Does the addition of whole-body MRI to routine imaging influence real-world treatment decisions in metastatic breast cancer.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/publicdomain/zero/1.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/publicdomain/zero/1.0/